Molecular Templates, Inc.
Molecular Templates, Inc. (MTEM): 8 pipeline candidates · ~5 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
5.3 months
D/E 2.75 · 0% dilution
Lead: Approved
8 candidates
N/A
N/A
A transparent, data-derived signal for Molecular Templates, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$9.7M
Quarterly Burn
$5.9M
Runway
5.3 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| abbott realtime idh1 | — |
| albunex echocardiography contrast microspheres | Approved |
| cobas ebv | — |
| cobas vivodx mrsa | — |
| mt-0169 | Preclinical |
| mt-6402 | Phase 1 |
| mt-8421 | Phase 1 |
| simplexa c. auris direct | — |
Frequently asked questions
How many drug candidates are in Molecular Templates, Inc.'s pipeline?
Molecular Templates, Inc. (MTEM) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Molecular Templates, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Molecular Templates, Inc. has approximately 5.3 months of cash runway.
Who is the CEO of Molecular Templates, Inc.?
Dr. Eric E. Poma Ph.D. is the chief executive officer of Molecular Templates, Inc. (MTEM).
Get the full picture on Molecular Templates, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.